ANDA 202686, held by PharmoBedient. Esomeprazole Sodium.
As of Nov 21, 2026, ANDA 202686 (Esomeprazole Sodium), held by PharmoBedient, was first approved by FDA on May 17, 2017, with 5 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 17, 2017 | Original application | Approved | None posted |
| Esomeprazole SodiumEQ 20MG BASE/VIAL ยท injectable;intravenous | Esomeprazole Sodium | Discontinued |
| Esomeprazole SodiumEQ 40MG BASE/VIAL ยท injectable;intravenous | Esomeprazole Sodium | Discontinued |
| Oct 11, 2024 | Supplement 3Labeling ยท Standard review | Approved | None posted |
| Oct 11, 2024 | Supplement 5Labeling ยท Standard review | Approved | None posted |
| Oct 11, 2024 | Supplement 7Labeling ยท Standard review | Approved | None posted |
| Oct 11, 2024 | Supplement 9Labeling ยท Standard review | Approved | None posted |
| Oct 11, 2024 | Supplement 10Labeling ยท Standard review | Approved | None posted |
| May 17, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. โWhat FDA's review saysโ is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters